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Background. Small-for-size syndrome (SFSS) occurs in the presence of insufficient livermass tomaintain normal function after liver
transplantation. Murine mortality following 85% hepatectomy can be reduced by the use of soluble receptor for advanced glycation
end products (sRAGE) to scavenge damage-associated molecular patterns and prevent their engagement with membrane-bound
RAGE. Aims. To explore serum levels of sRAGE, high-mobility group box-1 (HMGB1) protein, and other soluble inflammatory
mediators in a fatal case of SFSS.Methods. Serum levels ofHMGB1, sRAGE, IL-18, and other inflammatorymediatorsweremeasured
by ELISA in a case of SFSS, and the results were compared with 8 patients with paracetamol-induced acute liver failure (ALF)
and 6 healthy controls (HC). Results. HMGB1 levels were markedly higher in the SFSS patient (92.1 ng/mL) compared with the
ALF patients (median (IQR) 11.4 (3.7–14.8) ng/mL) and HC (1.42 (1.38–1.56) ng/mL). In contrast, sRAGE levels were lower in the
SFSS patient (1.88 ng/mL) compared with the ALF patients (3.53 (2.66–12.37) ng/mL) and were similar to HC levels (1.40 (1.23–
1.89) ng/mL). Conclusion. These results suggest an imbalance between pro- and anti-inflammatory innate immune pathways in
SFSS. Modulation of the HMGB1-RAGE axis may represent a future therapeutic avenue in this condition.
1. Introduction
The capacity for liver regeneration is finite, placing a restric-
tion upon theminimummass of liver tissue required tomain-
tain hepatic function following split liver transplantation (LT)
or liver resection. Small-for-size syndrome (SFSS) occurs in
the presence of insufficient liver mass to maintain normal
function and is characterised by severe graft dysfunction and
increased ascites output [1]. The pathophysiology of SFSS
is multifactorial, involving insufficient graft volume, poor
graft quality, and excessive portal inflow [2]. Amplification
of proinflammatory mediators in the remnant tissue is
also recognised to play an important role in limiting liver
regeneration [3]. Recent murine studies have suggested that a
key pathway in this process involves the receptor for advanced
glycation end products (RAGE), a cell-surface multiligand
pattern recognition receptor linked with amplification of the
innate inflammatory response to cell death. Engagement of
membrane-bound RAGE with ligands such as high-mobility
group box 1 (HMGB1) protein sustains inflammatory
responses and promotes apoptosis in the hepatic remnant
following massive hepatectomy [4]. Soluble RAGE (sRAGE),
the truncated extracellular domain of RAGE, appears to
act as a scavenger of RAGE ligands, thereby preventing
membrane-bound RAGE activation. Infusion of sRAGE
has been shown to significantly improve murine mortality
following 85% hepatectomy [4], but, to date, HMGB1 and
sRAGE expression have not been examined in human SFSS.
2. Case Description
A65-year-oldCaucasian female underwent cadaveric split LT
for liver failure secondary to primary biliary cirrhosis (PBC).
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PBC was diagnosed 14 years earlier on the basis of a positive
anti-mitochondrial antibody, cholestatic liver function tests,
and a confirmatory liver biopsy. At the time of operation she
weighed 47 kg with Child-Pugh andmodel for end stage liver
disease scores of 8 and 16 points, respectively. She received
a 500 g cadaveric left liver (segments I, II, III, and IV) graft,
with a graft weight-to-recipient body weight ratio of 1.1%.
The operation was uneventful, with a total blood volume loss
of 680mls. A routine postoperative ultrasound confirmed
patent portal and hepatic artery inflow and patent hepatic
venous outflow. Protocol immunosuppression consisted of
tacrolimus, azathioprine, and prednisolone. By 7 days after
LT, her clinical condition and transaminases had deteriorated
markedly, with an alanine aminotransferase level rising from
69 IU/L preoperatively to 1035 IU/L. She underwent tran-
sjugular liver biopsy which demonstrated extensive haem-
orrhagic parenchymal, perivenular, and periportal necrosis
consistent with portal hyperperfusion. Simultaneous hepatic
venography demonstrated a gradient of 12mmHg between
the left hepatic vein and right atrium with no angiographi-
cally significant stenosis. Her clinical condition continued to
deteriorate with rapid accumulation of ascites and she was
reintubated and ventilated, and received significant inotropic
and renal support. Repeat laparotomy demonstrated a con-
gested liver with large volumes of intra-abdominal ascites.
Due to continued clinical and biochemical deterioration she
was listed for super urgent LT but died on the 11th day after
LT before a second graft became available.
3. Methods
The study was prospectively approved by the Scotland “A”
Research Ethics Committee. Informed consent or assent was
obtained from all patients or the patient’s nominated next
of kin prior to study inclusion. Serum and plasma samples
obtained from the peripheral circulation of the SFSS subject
10 days following LTwere centrifuged at 1000 g for 15minutes
at 4∘C within one hour following collection. Samples were
immediately aliquoted and stored in polypropylene tubes at
−80∘C until analysis for soluble inflammatory mediators. As
a pathological comparator group, samples obtained in an
identical manner from 8 patients with fulminant acute liver
failure (ALF) secondary to paracetamol (acetaminophen)
poisoning were analysed. Four of these paracetamol over-
dose patients died whilst the other 4 patients underwent
emergency LT. At the time of blood sampling, 7 of the 8
paracetamol patients were mechanically ventilated, and all
8 were receiving both inotropic support and continuous
veno-veno haemofiltration. All 8 paracetamol patients were
in grade 3-4 hepatic encephalopathy at the time of blood
sampling.
3.1. HMGB1 Enzyme-Linked Immunosorbent Assay (ELISA).
Serum HMGB1 levels were measured using a commer-
cial quantitative sandwich ELISA (Shino-Test Corporation,
Japan) according to the manufacturer’s instructions. Each
sample was analysed in duplicate following appropriate
dilutions. Results were determined from a standard curve
prepared from 6 human HMGB1 standards ranging from 2.5
to 80 ng/mL. The coefficient of variation (CV) was 2.1%.
3.2. Soluble RAGE ELISA. Serum sRAGE levels were mea-
sured using a commercial quantitative sandwich ELISA
(R&D Systems, Abingdon, UK). Each sample was analysed
in duplicate following appropriate dilutions and results were
obtained from a standard curve prepared from 7 human
sRAGE standards ranging from 78 to 5000 pg/mL, with a CV
of 1.4%.
3.3. IL-2 sR𝛼, IL-18, and Neopterin ELISAs. Serum soluble
IL-2 receptor alpha (IL-2 sR𝛼), IL-18, and neopterin levels
were measured using commercial quantitative sandwich
ELISAs (R&D Systems Europe, Abingdon, UK; MBL Inter-
national Corporation, Woburn, MA; and Demeditec Diag-
nostics, Kiel, Germany, resp.) according to themanufacturer’s
instructions. The CVs for these ELISAs were 1.0%, 2.7%, and
1.8%, respectively.
3.4. Serum IL-6 and IL-10. Measurements were performed
using a cytometric bead array kit and software (BD Bio-
sciences, San Jose, CA) according to the manufacturer’s
instructions, with cytokine analysis performed on a FACSAr-
ray flow cytometer (BD Biosciences, San Jose, CA).
4. Results
Levels of HMGB1 were markedly higher in the SFSS patient
(92.1 ng/mL) compared with the paracetamol overdose
patients (median (interquartile range) 11.4 (3.7–14.8) ng/mL,
𝑛 = 8) and healthy controls (1.42 (1.38–1.56) ng/mL, 𝑛 =
6). In contrast, sRAGE levels were lower in the SFSS
patient (1.88 ng/mL) compared with the paracetamol over-
dose patients (3.53 (2.66–12.37) ng/mL, 𝑛 = 8) and were
similar to healthy controls (1.40 (1.23–1.89) ng/mL, 𝑛 = 6).
Further analysis of these data demonstrated considerably
higher HMGB1: sRAGE levels in the SFSS patient (49.1)
compared with the paracetamol overdose patients (1.7 (0.7–
4.8), 𝑛 = 8). The HMGB1 level remained at a similar level
(82.7 ng/mL) in the SFSS patient on the 11th postoperative
day.
4.1. IL-18 Levels. Following massive hepatic resection RAGE
is upregulated on murine mononuclear phagocyte-derived
dendritic cells (DCs) rather than hepatocytes [4]. DCs inter-
act closely with natural killer cells to promote reciprocal mat-
uration and activation, a process dependent upon secreted
HMGB1, RAGE, and the cytokine interleukin (IL)-18 [5].
IL-18 levels in the SFSS patient were extremely elevated at
20880 pg/mL compared with both the paracetamol overdose
cohort (527.7 (348.4–745.4) pg/mL, 𝑛 = 8) and healthy con-
trols (16.3 (10.5–90.9) pg/mL, 𝑛 = 6).
4.2. Immune Activation. Overall activation of the lympho-
cyte and monocyte components of the immune response
was assessed by measuring levels of soluble IL-2 sR𝛼, a
marker of T-cell activation, and neopterin, a marker of 𝛾-
interferon mediated macrophage activation. IL-2 R𝛼 levels
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were markedly increased in the SFSS patient (39.7 ng/mL)
compared with the paracetamol overdose patients (4.4 (3.2–
11.8) ng/mL, 𝑛 = 8) and healthy controls (1.7 (1.3–1.8) ng/mL,
𝑛 = 6). Likewise, neopterin levels were considerably higher in
the SFSS patient (238.6 ng/mL) compared with the paracet-
amol-induced ALF patients (132.1 (83.9–161.7) ng/mL, 𝑛 = 8)
and healthy controls (11.4 (9.4–15.7) ng/mL, 𝑛 = 6).
4.3. Regenerative and Anti-Inflammatory Cytokines. Massive
hepatic resection may lead to impaired tissue regeneration
and reduced anti-inflammatory responses to tissue injury.We
measured levels of IL-6, an important regenerative cytokine
normally upregulated following liver injury, and IL-10, a key
anti-inflammatory cytokine, using a human inflammatory
cytokine bead array. IL-6 levels were similar in both the
SFSS patient (3518 pg/mL) and the paracetamol-induced ALF
patients (4018 (1160–5000) pg/mL) whilst levels of IL-10 were
only marginally raised in the SFSS patient (1350 pg/mL)
compared with the paracetamol overdose cohort (556 (225–
1969) pg/mL, 𝑛 = 8).
5. Discussion
This study suggests that an imbalance in the HMGB1-RAGE
axis may be involved in the pathogenesis of SFSS. Compared
with a cohort of critically ill paracetamol overdose patients,
all of whom died or required emergency LT, this SFSS patient
exhibited eightfold higher HMGB1 levels, but lower levels of
the HMGB1 scavenger sRAGE. Levels of IL-18, a key cytokine
involved in DC and natural killer cell maturation, were
extremely elevated in the SFSS patient compared with the
paracetamol patients, as were IL-2 R𝛼 and neopterin,markers
of T-cell and macrophage activation, respectively. However,
levels of regenerative and anti-inflammatory cytokines were
similar in both the SFSS and paracetamol patients. Impor-
tantly, both the SFSS and paracetamol patients had similar
systemic organ failure assessment scores and organ support
requirements, suggesting that the inflammatory dysregula-
tion seen in the SFSS patient was not simply a consequence
of greater multiorgan failure.
This case fulfils recognised definitions of SFSS given the
onset of symptoms within a week of LT, the prolonged hyper-
bilirubinaemia, coagulopathy, encephalopathy, and absence
of outflow obstruction [6]. However, we recognise that there
are limitations to the conclusions that can be drawn from
a single case, particularly since blood samples were only
available from the 10th postoperative day. It is possible that
the immune dysregulation seen in this case stems from
cold or warm ischaemia at the time of LT. HMGB1 is
rapidly released into the systemic circulation following liver
reperfusion after LT, with HMGB1 levels correlating with
the degree of graft steatosis and postoperative ALT levels
[7]. However in the study by Ilmakunnas et al., HMGB1
levels fell rapidly within 1-2 hours of reperfusion after cold
ischemia, suggesting that the high levels seen in our patient
at 10 days postoperatively are unlikely to be directly related
to preservation injury [7]. Interestingly, peripheral HMGB1
levels were considerably higher in our SFSS patient, using the
same ELISA system, than those reported by Ilmakunnas et al.
(range 2–40 ng/mL) following reperfusion in their post-LT
cohort. The increased levels of HMGB1 may also reflect
unrecognised systemic infection, particularly since there is
impaired systemic immune function and decreased acute
phase protein production following hepatectomy, and the
ability of the host to fight systemic infection may also be
impaired following a small-for-size graft [8, 9].
HMGB1, a regulatory nuclear protein involved in DNA
transcription, is now recognized to have an important
additional role as a damage-associated molecular pattern
(DAMP) [10]. Following necrotic cell death hypoacetylated
HMGB1 leaks from damaged cells where it can function as
a danger signal to other cells and activate innate and adap-
tive immune responses [11]. Additionally, hyperacetylated
HMGB1 is actively secreted by immune cells and can function
as a cytokine [12, 13]. HMGB1 can activate a host of down-
stream effects including nuclear factor (NF)-𝜅B signalling,
endothelial cell activation, and DC maturation [14]. Much
attention has been focused upon HMGB1 as a late mediator
of sepsis [10], but HMGB1 levels are also increased in a
number of other acute and chronic inflammatory disorders
[15, 16]. HMGB1 has been shown to play a role in experi-
mental models of both paracetamol-induced hepatotoxicity
[11, 17, 18] and ischaemia-reperfusion injury [19, 20]. The
proinflammatory effects of HMGB1 may be enhanced by the
formation of complexes with other inflammatory mediators
such as IL-1𝛽, nucleosomes, and lipopolysaccharide which
then interact with a variety of receptors including RAGE [21].
Following HMGB1 stimulation, macrophages derived from
RAGE knockout mice produce significantly lower amounts
of proinflammatory and regenerative cytokines, but it is also
important to note that HMGB1 can also act independently
of RAGE via toll-like receptors −2, −4, and −9 and thus
RAGE −/−mice are not completely protected from the effects
of HMGB1 [22]. HMGB1 is also known to promote tissue
regeneration and can modulate both endothelial and bone
marrow stem cell function [16]. In vivo, HMGB1 can recruit
mesoangioblasts to injured skeletal muscle and promote
regeneration of skin wounds and cardiac muscle [23, 24].
It is noteworthy that the beneficial effects of HMGB1 upon
stem cell migration and tissue repair are achieved at serum
levels considerably lower than those seen in mice with septic
shock, suggesting a possible threshold effect for HMGB1
beyond which tissue regeneration is overtaken by damage
from infiltrating inflammatory cells.
Widespread application of cadaveric split LT or liv-
ing donor LT could significantly improve the numbers of
available organs for transplantation, but these options are
currently limited by the need to provide sufficient functioning
liver cell volume to the recipient. The use of a right hemi-
hepatectomy from a liver donor places a healthy individual
at significant operative risk, whilst a cadaveric graft rarely has
sufficient liver volume to permit successful splitting to two
adult recipients. Therefore, strategies to protect small grafts
are urgently needed. Several animal studies have recognized
enhanced innate immune response following small volume
grafts [25–27], and recently membrane-bound RAGE was
implicated in driving deleterious responses followingmassive
murine liver resection [4]. RAGE can engage a variety of
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structurally diverse DAMPs, including HMGB1, released
from dying cells. Engagement of membrane-bound RAGE
with its various ligands sustains inflammatory responses in
part through production of reactive oxygen intermediates
and sustained activation of NF-𝜅B and mitogen-activated
protein kinase pathways [28]. Modulation of HMGB1-RAGE
binding could therefore influence cytokine production, cellu-
lar oxidant stress, and cell survival/proliferation. The poten-
tial beneficial effects of hepatic RAGE modulation have
already been demonstrated experimentally in the context of
paracetamol hepatotoxicity and ischaemia/reperfusion injury
[29, 30], as well as following massive liver resection [4]. This
suggests that RAGE may mediate a similar response to a
number of different hepatic injuries and, as such, represents
an attractive therapeutic target. However, exogenous sRAGE
treatment produced only a modest benefit in a murine model
of caecal ligation and puncture [31], and other caveats include
a potential deleterious response when used during active
bacterial infection [32].
The markedly increased levels of IL-18, neopterin, and
IL-2 sR𝛼 in this case provide further evidence to support
a role for macrophages and T cells in the pathogenesis of
SFSS. A rat model utilizing small-for-size liver allografts
demonstrated intensemacrophage infiltration of the allograft
by 72 hours, with increased IL-2 mRNA expression, sug-
gesting that macrophages might accelerate cellular rejection
in this syndrome in part through alloantigen presentation
and adaptive immune activation [25]. Future animal studies
should explore the temporal changes inHMGB1 levels follow-
ing small-for-size allografting and determine the relationship
between macrophage infiltration and HMGB1 expression in
the liver remnant. In summary, SFSS remains a significant
risk following split LT and major liver resection and this case
sheds light upon the pathophysiology of this condition and,
combined with the findings from previous animal studies in
this area, suggests thatmodulation of theHMGBI-RAGE axis
may represent a novel future therapeutic avenue.
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